The Department of health and human services (HHS) Saturday, may 9, announced the plan of distribution of the drug “Ramdevpir”, which was donated to the United States manufacturer, Gilead Sciences. This is stated in the message published on the website of the Department, writes “Voice of America”.
HHS decided to send the donated dose “of Ramdevpir” primarily in areas of the country most affected by the outbreak COVID-19. Starting the evening of 7 may, 30 boxes with the drug was sent to Connecticut, 140, in Illinois, 10 in Iowa, 30 in Maryland, 40 in Michigan and 110 boxes were sent to new Jersey. Each box contains 40 bottles with the drug, which is administered intravenously.
“Ramdevpir” has already received in Indiana (38 boxes), Massachusetts (117 boxes), new Jersey (94 boxes), new York (565 cartons), Rhode island (30 boxes), tn (7 boxes) and Virginia (33 boxes).
Gilead Sciences has pledged free supply of about 607 000 bottles with an experimental drug within the next six weeks. This will be enough to treat approximately 78 000 hospitalized patients with COVID-19 in serious condition. Globally, the company will donate 1.5 million bottles medicines, which is currently considered one of the most effective in the fight against COVID-19.
The health departments of the States will distribute the drug to the appropriate hospital, taking into account the severity of the patients who need the medicine. First and foremost donated to “Ramdevpir” get the patients on the ventilators, or people who have been critically low levels of oxygen in the blood (below 94%).
Preliminary results of a clinical trial, which was conducted by the National institutes of health, in conjunction with Gilead Sciences, has shown that the use of “Ramdevpir” leads to faster recovery of patients. The obtained data is still insufficient in order to determine whether the drug can reduce the mortality rate among critically ill patients.
The drug is expected to be delivered to all 50 States and all territory included in the United States, and to the Administration of health of veterans and the health Service native Americans.
In addition to the donated doses for hospitalized patients in the United States and other countries, “Ramdevpir” in the United States can also get a clinical trials.
Management on sanitary inspection behind quality of foodstuff and medicines (FDA) has granted emergency permission to use the “Ramdevpir” may 1, allowing doctors to prescribe the drug for the treatment of the suspect or laboratory-confirmed case COVID-19 in adults and children who have been hospitalized and are in serious condition.
As previously wrote ForumDaily:
According to the data, based on observations of patients, more than two thirds of critically ill patients with COVID-19 condition has improved after treatment, “Redecision”.
On may 1, the Administration for quality control of medicines and food USA (FDA) approved the emergency use of the experimental drug “Ramdevpir” when treating patients infected with the coronavirus.